Published in
Impact Journals, Oncotarget, 3(3), p. 236-260, 2012
Links
- ORCID
- Impact Journals
- [www.ncbi.nlm.nih.gov] | PDF
- [hdl.handle.net]
- [thescholarship.ecu.edu] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
Journal article published in 2012 by
Melchiorre Cervello,
James A. McCubrey 
,
Antonella Cusimano,
Nadia Lampiasi,
Antonina Azzolina,
Giuseppe Montalto
,
Antonella Cusimano,
Nadia Lampiasi,
Antonina Azzolina,
Giuseppe Montalto
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Hepatocellular carcinoma (HCC) is the most common liver cancer, accounting for 90% of primary liver cancers. In the last decade it has become one of the most frequently occurring tumors worldwide and is also considered to be the most lethal of the cancer systems, accounting for approximately one third of all malignancies.